These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33335437)

  • 1. Effects of Bisphosphonate Therapy on Bone Mineral Density in Boys with Duchenne Muscular Dystrophy.
    Ronsley R; Islam N; Kang M; Nadel H; Reilly C; Metzger D; Selby K; Panagiotopoulos C
    Clin Med Insights Endocrinol Diabetes; 2020; 13():1179551420972400. PubMed ID: 33335437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
    Sbrocchi AM; Rauch F; Jacob P; McCormick A; McMillan HJ; Matzinger MA; Ward LM
    Osteoporos Int; 2012 Nov; 23(11):2703-11. PubMed ID: 22297733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.
    Zheng WB; Dai Y; Hu J; Zhao DC; Wang O; Jiang Y; Xia WB; Xing XP; Li M
    Endocr Pract; 2020 Dec; 26(12):1477-1485. PubMed ID: 33471740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy.
    Zacharin M; Lim A; Gryllakis J; Siafarikas A; Jefferies C; Briody J; Heather N; Pitkin J; Emmanuel J; Lee KJ; Wang X; Simm PJ; Munns CF
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2328-2342. PubMed ID: 33954789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
    Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Smit K; Walker S; Hartigan C; Khan N; Konji VN; MacLeay L; Page M; Sykes E; Robinson ME; Alos N; Cummings EA; Ho J; Sbrocchi AM; Stein R; Saleh D; Craven BC; Dang UJ; Siminoski K; Rauch F; Ward LM
    Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
    Suthar R; Reddy BVC; Malviya M; Sirari T; Attri SV; Patial A; Tageja M; Didwal G; Khandelwal NK; Saini AG; Saini L; Sahu JK; Dayal D; Sankhyan N
    J Pediatr Endocrinol Metab; 2021 May; 34(5):573-581. PubMed ID: 33838091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
    Zhou L; Zhou H; Xu H; Sun X; Chen X; Fan P; Cai X; Wang Q
    Osteoporos Int; 2024 Jun; 35(6):997-1005. PubMed ID: 38277031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
    Moretti A; Liguori S; Paoletta M; Gimigliano F; Iolascon G
    Adv Ther; 2022 Jul; 39(7):3308-3315. PubMed ID: 35614293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histomorphometry and Bone Matrix Mineralization Before and After Bisphosphonate Treatment in Boys With Duchenne Muscular Dystrophy: A Paired Transiliac Biopsy Study.
    Misof BM; Roschger P; McMillan HJ; Ma J; Klaushofer K; Rauch F; Ward LM
    J Bone Miner Res; 2016 May; 31(5):1060-9. PubMed ID: 26615086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
    Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
    Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic oral bisphosphonate therapy in duchenne muscular dystrophy.
    Srinivasan R; Rawlings D; Wood CL; Cheetham T; Moreno AC; Mayhew A; Eagle M; Guglieri M; Straub V; Owen C; Bushby K; Sarkozy A
    Muscle Nerve; 2016 Jun; 54(1):79-85. PubMed ID: 26599341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone Mineral Density Assessment by Quantitative Computed Tomography in Glucocorticoid-Treated Boys With Duchenne Muscular Dystrophy: A Linear Mixed-Effects Modeling Approach.
    Liu C; Yang DD; Zhang L; Lei XG; Jia FL; Liao Y; Chen XJ; Ning G; Luo W; Qu HB
    Front Endocrinol (Lausanne); 2022; 13():860413. PubMed ID: 35399923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
    Bourke JP; Bueser T; Quinlivan R
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment for osteoporosis in people with beta-thalassaemia.
    Bhardwaj A; Swe KMM; Sinha NK
    Cochrane Database Syst Rev; 2023 May; 5(5):CD010429. PubMed ID: 37159055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced bone mineral density in adolescents with Duchenne Muscular Dystrophy (DMD) and scoliosis.
    Tsaknakis K; Jäckle K; Lüders KA; Lorenz HM; Braunschweig L; Hell AK
    Osteoporos Int; 2022 Sep; 33(9):2011-2018. PubMed ID: 35583603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
    Joseph S; Wang C; Bushby K; Guglieri M; Horrocks I; Straub V; Ahmed SF; Wong SC;
    JAMA Neurol; 2019 Jun; 76(6):701-709. PubMed ID: 30855644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
    Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
    Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
    Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
    Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interventions to prevent and treat corticosteroid-induced osteoporosis and prevent osteoporotic fractures in Duchenne muscular dystrophy.
    Bell JM; Shields MD; Watters J; Hamilton A; Beringer T; Elliott M; Quinlivan R; Tirupathi S; Blackwood B
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010899. PubMed ID: 28117876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.